ALIVECOR®

The UK's most advanced personal ECG outside the hospital

KardiaMobile 6L is a six-lead personal ECG that records more heart data than any smartwatch, right on your phone. Better understand your heart health with Kardia's medical-grade ECGs.

- **Advanced ECG technology** used by the NHS.
- **Recommended** by NICE.
- **Six-lead personal ECG device** (records leads I, II, III, aVL, aVR, and aVF).
- **More lead data** gives you and your doctor deeper insights on your heart rhythm.
- **Detects common arrhythmias,** including atrial fibrillation, a leading cause of stroke.
- **Easily record and save** accurate heart data on your phone.

For more information, scan the QR code or visit store.alivecor.co.uk.

References: www.nice.org.uk/guidance/mtg64, www.nice.org.uk/guidance/hte10

Opportunistic AF Detection with KardiaMobile

Atrial Fibrillation (AF) is a significant global health challenge, with millions affected and a substantial number remaining undiagnosed until a major event, such as a stroke, occurs.

Opportunistic **AF detection** involves seamlessly integrating AF screening into routine patient interactions. This proactive approach is a vital and cost-effective strategy to:

- Identify high-risk individuals earlier.
- Significantly reduce the burden of AF-related strokes.
- Improve patient outcomes and reduce healthcare costs..

KardiaMobile: Empowering Your Practice with Seamless AF Screening

AliveCor's KardiaMobile is a clinically validated, portable ECG device designed to empower healthcare professionals. It enables you to effortlessly incorporate medical-grade AF screening into your existing workflows, aligning with modern healthcare priorities such as the Network Contract Directed Enhanced Service (DES) 2025/26[2].

KardiaMobile Aligns with Strategic Healthcare Priorities

KardiaMobile closely aligns with initiatives like the DES 2025/26[2], which focuses on improving health outcomes and reducing inequalities through proactive CVD prevention and early detection.

Accelerated AF Detection: Supports opportunistic pulse checks alongside blood pressure monitoring, delivering fast, accurate ECG recordings at the point of care.

Proactive CVD Risk Management: Enables early identification of abnormal heart rhythms, helping clinicians address cardiovascular disease risks before they escalate.

Expanded Diagnostic Reach: Enhances AF diagnostic capabilities as part of the ABC pathway (Atrial Fibrillation, Blood Pressure, Cholesterol), supporting healthcare teams in fulfilling their targets.

Proven Effectiveness and Accuracy in Real-World Settings and Clinical Trials:

Real-World Impact and High Detection Rates: A study by Lang et al. (2020)[1] demonstrated the clinical benefit of mobile ECG devices, including KardiaMobile, in AF detection across various community and clinical settings.
Study Scope: This assessment deployed 400 devices across 12 South London boroughs.

Key Finding: Mobile ECGs clinically proven to improve AF detection, particularly in high-risk populations, enabling earlier diagnosis and intervention.

Reach and Results: KardiaMobile was used to test over 10,000 people, identifying 537 possible AF cases. This approach, which showed higher sensitivity and specificity than manual pulse palpation[2], found the most undiagnosed AF patients in GP practices, outpatient clinics, and community teams.



Key Benefits for Your Healthcare Setting:

Enhanced Stroke Prevention: Early AF identification allows for timely anticoagulation, potentially reducing AF-related strokes and improving patient outcomes.

Significant Cost Savings: For every 25 people diagnosed with AF and appropriately treated with anticoagulation, one stroke is prevented, saving an average of £46,039 per stroke in health and social care costs over 5 years[3].

Portable and Easy-to-Use: KardiaMobile seamlessly integrates into various clinical workflows, making AF detection more accessible and efficient.

Scalable and Efficient: Its proven accuracy and automated analysis reduce manual review burden, making it ideal for large-scale opportunistic screening and eHealth programs.

References

1. Lang, D. et al. (2020). Using mobile ECG devices to increase detection of atrial fibrillation across a range of settings in south London. *Future Healthcare Journal*, 7(1), 86-89.

2. Taggar, J. S. et al. (2016). Accuracy of methods for detecting an irregular pulse and suspected atrial fibrillation: a systematic review and meta-analysis. *Eur J Prev Cardiol*, 23, 1330–8.

3. Xu, X. M. et al. (2018). The economic burden of stroke care in England, Wales and Northern Ireland: Using a national stroke register to estimate and report patient-level health economic outcomes in stroke. *Eur Stroke J*, 3, 82–91.

4. Slaats, B. M. I. et al. (2023). Can eHealth programs for cardiac arrhythmias be scaled-up by using the KardiaMobile algorithm? *Cardiovasc Digit Health J*, 5(2), 78-84. doi: 10.1016/j.cvdhj.2023.11.004. PMID: 38765619; PMCID: PMC11096654.

5. NHS England. (2025/26). Network Contract Directed Enhanced Service Guidance. Available at: https://www.england.nhs.uk/publication/network-contract-directed-enhanced-service-guidance-in-england-part-a-clinical-and-support-servicessection-8/

ALIVECOR®

For more information, email us at ousenquiries@alivecor.com or scan the QR code to contact us directly.